Vascular endothelial growth factor VEGF-like heparin-binding protein from the venom of Vipera aspis aspis (Aspic viper)

被引:48
作者
Komori, Y [1 ]
Nikai, T
Taniguchi, K
Masuda, K
Sugihara, H
机构
[1] Meijo Univ, Fac Pharm, Dept Microbiol, Tenpaku Ku, 150 Yagotayama, Nagoya, Aichi 4688503, Japan
[2] Meijo Univ, Fac Pharm, Analyt Ctr, Tenpaku Ku, Nagoya, Aichi 4688503, Japan
关键词
D O I
10.1021/bi990562z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The heparin-binding dimeric hypotensive factor (HF) was purified from Vipera aspis aspis (Aspic viper) venom [Komori, Y. and Sugihara, H. (1990) Toxicon 28, 359-369]. In this study, the amino acid sequence, and structure and function of HF, were elucidated. By electrospray ionization mass spectrometry (ESI-MS), the molecular weight of HF was determined to be 25 072.1. The complete amino acid sequence of HF was determined by Edman sequencing of the S-pyridylethylated HF and its peptides derived from enzymatic digestion. The theoretical molecular mass calculated from the primary structure agrees well with the molecular weight determined by ESI-MS. HF consists of two homogeneous monomers bound covalently. The monomer with an N-terminal blocked by pyroglutamic acid contains 110 amino acid residues, including eight cysteine residues, two of which are considered to be involved in intermolecular disulfide bonds. Sequential homology search revealed that the primary structure of HF is similar to that of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) with a sequential homology of 45 and 22%, respectively. When injected intradermally into a rat, an increase in capillary permeability was observed with HF or VEGF. On the other hand, only HF exerted a strong hypotensive effect after intravenous injection of samples into a rat. Purified HF has a mitogenic effect on endothelial cells. Through the use of bovine aortic endothelial cells (BAEC), the half-maximal mitogenic concentration of HF was determined to be 5-5.5 nM (125-138 ng/mL). Similarly, VEGF had a mitogenic concentration at 0.5-1 nM. When incubated with I-IF and cycloheximide or HF and heparin, the cell growth was inhibited, suggesting that the mechanism of action of HI; is similar to that of VEGF.
引用
收藏
页码:11796 / 11803
页数:8
相关论文
共 42 条
[1]  
ANDERSSON M, 1992, J BIOL CHEM, V267, P11260
[2]   CDNA SEQUENCE AND CHROMOSOMAL LOCALIZATION OF HUMAN PLATELET-DERIVED GROWTH-FACTOR A-CHAIN AND ITS EXPRESSION IN TUMOR-CELL LINES [J].
BETSHOLTZ, C ;
JOHNSSON, A ;
HELDIN, CH ;
WESTERMARK, B ;
LIND, P ;
URDEA, MS ;
EDDY, R ;
SHOWS, TB ;
PHILPOTT, K ;
MELLOR, AL ;
KNOTT, TJ ;
SCOTT, J .
NATURE, 1986, 320 (6064) :695-699
[3]   TUMOR VASCULAR-PERMEABILITY FACTOR STIMULATES ENDOTHELIAL-CELL GROWTH AND ANGIOGENESIS [J].
CONNOLLY, DT ;
HEUVELMAN, DM ;
NELSON, R ;
OLANDER, JV ;
EPPLEY, BL ;
DELFINO, JJ ;
SIEGEL, NR ;
LEIMGRUBER, RM ;
FEDER, J .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (05) :1470-1478
[4]  
CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017
[5]   Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor [J].
Dougher, AM ;
Wasserstrom, H ;
Torley, L ;
Shridaran, L ;
Westdock, P ;
Hileman, RE ;
Fromm, JR ;
Anderberg, R ;
Lyman, S ;
Linhardt, RJ ;
Kaplan, J ;
Terman, BI .
GROWTH FACTORS, 1997, 14 (04) :257-268
[6]   PITUITARY FOLLICULAR CELLS SECRETE A NOVEL HEPARIN-BINDING GROWTH-FACTOR SPECIFIC FOR VASCULAR ENDOTHELIAL-CELLS [J].
FERRARA, N ;
HENZEL, WJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) :851-858
[7]   VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].
FERRARA, N .
TRENDS IN CARDIOVASCULAR MEDICINE, 1993, 3 (06) :244-250
[8]   Vascular endothelial growth factor [J].
Ferrara, N .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (14) :2413-2422
[9]   ISOLATION OF BRADYKININ-POTENTIATING PEPTIDES FROM BOTHROPS-JARARACA VENOM [J].
FERREIRA, SH ;
BARTELT, DC ;
GREENE, LJ .
BIOCHEMISTRY, 1970, 9 (13) :2583-&
[10]   A BRADYKININ-POTENTIATING FACTOR ( BPF ) PRESENT IN VENOM OF BOTHROPS JARARACA [J].
FERREIRA, SH .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1965, 24 (01) :163-&